Welcome to our dedicated page for Bristol Myers SEC filings (Ticker: BMYMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Bristol Myers's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Bristol Myers's regulatory disclosures and financial reporting.
Bristol Myers Squibb EVP and CFO David V. Elkins reported open-market sales of company stock. On April 1, 2026, he sold 25,519 shares of common stock at a weighted average price of $61.60 per share and 4,481 shares at $62.05 per share, totaling 30,000 shares. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After the sales, he directly held 159,248 shares of Bristol Myers Squibb common stock and had an additional 294.42 shares held indirectly through the BMS Savings and Investment Program, based on a recent 401(k) plan statement.
Bristol Myers Squibb EVP and CFO David V. Elkins reported open-market sales of company stock. On April 1, 2026, he sold 25,519 shares of common stock at a weighted average price of $61.60 per share and 4,481 shares at $62.05 per share, totaling 30,000 shares. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After the sales, he directly held 159,248 shares of Bristol Myers Squibb common stock and had an additional 294.42 shares held indirectly through the BMS Savings and Investment Program, based on a recent 401(k) plan statement.
Bristol Myers Squibb director Phyllis R. Yale received 577.082 Deferred Share Units as a compensation award. The grant was valued at $60.65 per unit and is linked to an equal number of underlying common shares. Following this award, she holds 43,903.777 Deferred Share Units in total.
The units will convert into common stock when she leaves the board or on a future date she previously chose. Her balance includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Phyllis R. Yale received 577.082 Deferred Share Units as a compensation award. The grant was valued at $60.65 per unit and is linked to an equal number of underlying common shares. Following this award, she holds 43,903.777 Deferred Share Units in total.
The units will convert into common stock when she leaves the board or on a future date she previously chose. Her balance includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Theodore R. Samuels II received a grant of 845.012 Deferred Share Units as compensation. These units are tied to Bristol Myers Squibb common stock at a reference price of $60.65 per unit.
Each Deferred Share Unit converts into one share of common stock when his board service ends or on a future date he previously selected. Following this award, he holds a total of 68,727.516 Deferred Share Units, which also reflect deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Theodore R. Samuels II received a grant of 845.012 Deferred Share Units as compensation. These units are tied to Bristol Myers Squibb common stock at a reference price of $60.65 per unit.
Each Deferred Share Unit converts into one share of common stock when his board service ends or on a future date he previously selected. Following this award, he holds a total of 68,727.516 Deferred Share Units, which also reflect deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Derica W. Rice received a grant of 638.912 Deferred Share Units on common stock. The award is classified as a grant or other acquisition, not an open-market purchase or sale. Each unit will convert into one share of common stock upon settlement.
The Deferred Share Units become settleable when Rice ceases to be a director or at a future date previously specified. Following this grant, Rice holds a total of 39,963.721 Deferred Share Units, which include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Derica W. Rice received a grant of 638.912 Deferred Share Units on common stock. The award is classified as a grant or other acquisition, not an open-market purchase or sale. Each unit will convert into one share of common stock upon settlement.
The Deferred Share Units become settleable when Rice ceases to be a director or at a future date previously specified. Following this grant, Rice holds a total of 39,963.721 Deferred Share Units, which include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Michael R. McMullen received a grant of Deferred Share Units as board compensation. On March 31, 2026, he was awarded 577.082 Deferred Share Units, with a reference price of $60.65 per unit.
Each unit will convert into one share of common stock upon settlement, which occurs when he ceases to be a director or on a future date he previously selected. After this award, he holds 15,556.771 Deferred Share Units, including deferred compensation and reinvested dividends under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Michael R. McMullen received a grant of Deferred Share Units as board compensation. On March 31, 2026, he was awarded 577.082 Deferred Share Units, with a reference price of $60.65 per unit.
Each unit will convert into one share of common stock upon settlement, which occurs when he ceases to be a director or on a future date he previously selected. After this award, he holds 15,556.771 Deferred Share Units, including deferred compensation and reinvested dividends under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Peter J. Arduini received a grant of 577.082 Deferred Share Units, each tied to common stock valued at $60.65 per unit. After this compensation award, he directly holds a total of 71,435.166 Deferred Share Units.
Each Deferred Share Unit will convert into one share of common stock when the units are settled. Settlement occurs when Arduini ceases to be a director or on a future date he previously specified. The reported holdings include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Peter J. Arduini received a grant of 577.082 Deferred Share Units, each tied to common stock valued at $60.65 per unit. After this compensation award, he directly holds a total of 71,435.166 Deferred Share Units.
Each Deferred Share Unit will convert into one share of common stock when the units are settled. Settlement occurs when Arduini ceases to be a director or on a future date he previously specified. The reported holdings include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol-Myers Squibb Co ownership disclosure: The Vanguard Group filed Amendment No. 10 to report 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing states this reporting change follows an internal realignment and disaggregation of certain Vanguard subsidiaries in accordance with SEC Release No. 34-39538, with affected subsidiaries reporting separately after the realignment.
Bristol-Myers Squibb Co ownership disclosure: The Vanguard Group filed Amendment No. 10 to report 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing states this reporting change follows an internal realignment and disaggregation of certain Vanguard subsidiaries in accordance with SEC Release No. 34-39538, with affected subsidiaries reporting separately after the realignment.
Bristol Myers Squibb is asking shareholders at its virtual May 5, 2026 meeting to elect 11 directors, approve an advisory say‑on‑pay vote, adopt a 2026 Stock Award and Incentive Plan, ratify Deloitte & Touche LLP as auditor, and consider a proposal for an independent board chair.
The proxy highlights 2025 execution: the Growth Portfolio generated $26.4 billion in sales, up 17% over 2024, with seven products annualizing above $1 billion. The company reports 18 global regulatory approvals, completion of a $10 billion debt paydown target ahead of schedule, and a dividend raised for the 16th consecutive year.
Board materials emphasize strong governance, with 10 of 11 director nominees independent, active board refreshment, majority voting with resignation policies, extensive risk oversight, and integration of sustainability and social impact goals into strategy and executive incentives, including expanded use of AI in R&D and operations.
Bristol Myers Squibb is asking shareholders at its virtual May 5, 2026 meeting to elect 11 directors, approve an advisory say‑on‑pay vote, adopt a 2026 Stock Award and Incentive Plan, ratify Deloitte & Touche LLP as auditor, and consider a proposal for an independent board chair.
The proxy highlights 2025 execution: the Growth Portfolio generated $26.4 billion in sales, up 17% over 2024, with seven products annualizing above $1 billion. The company reports 18 global regulatory approvals, completion of a $10 billion debt paydown target ahead of schedule, and a dividend raised for the 16th consecutive year.
Board materials emphasize strong governance, with 10 of 11 director nominees independent, active board refreshment, majority voting with resignation policies, extensive risk oversight, and integration of sustainability and social impact goals into strategy and executive incentives, including expanded use of AI in R&D and operations.
Bristol Myers Squibb executive Hiroshi Chris Shibutani, EVP and Chief Strategy Officer, received equity-based compensation awards in the form of derivatives tied to the company’s common stock. On March 10, 2026, he was granted 7,837 Market Share Units and 11,755 Performance Shares at a price of $0.00 per unit.
Each market share unit represents a target number of shares that can convert into common stock based on a payout factor linked to total shareholder return and a relative TSR floor, with a minimum payout factor of 80% and a maximum of 225%. These market share units cliff vest on the third anniversary of the grant date, subject to the Board certifying performance results, and carry an expiration date of March 10, 2029.
Each performance share converts into one share of common stock upon distribution in the first quarter of 2029, also subject to certification of performance results by the Board. After these grants, reported holdings for these awards are 7,837 market share units and 11,755 performance shares, respectively.
Bristol Myers Squibb executive Hiroshi Chris Shibutani, EVP and Chief Strategy Officer, received equity-based compensation awards in the form of derivatives tied to the company’s common stock. On March 10, 2026, he was granted 7,837 Market Share Units and 11,755 Performance Shares at a price of $0.00 per unit.
Each market share unit represents a target number of shares that can convert into common stock based on a payout factor linked to total shareholder return and a relative TSR floor, with a minimum payout factor of 80% and a maximum of 225%. These market share units cliff vest on the third anniversary of the grant date, subject to the Board certifying performance results, and carry an expiration date of March 10, 2029.
Each performance share converts into one share of common stock upon distribution in the first quarter of 2029, also subject to certification of performance results by the Board. After these grants, reported holdings for these awards are 7,837 market share units and 11,755 performance shares, respectively.